Figure 3 | Leukemia

Figure 3

From: The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

Figure 3

(a) Hypomethylation of the tumor protein 73 (TP73) and cyclin-dependent kinase inhibitor 2B (CDKN2B) gene promoters in Kasumi-1 cells after treatment with AraC, 5AC, DAC or Zeb. Cytosine-phosphate-guanine (CpG) dinucleotide methylation was assessed by sequencing multiple cloned alleles obtained from PCR on bisulfite-treated genomic DNA. Each horizontal line represents an individual allele. Filled circles represent methylated CpG sites; open circles, unmethylated CpG sites; gray circles, no data. The position of each cytosine nucleotide relative to the transcription start site is indicated at the top. (b) MassARRAY analysis to quantify DNA methylation of TP73, CDKN2B, CEBPA promoter sequences and global LINE1 sequences in untreated Kasumi-1 blasts and in cells treated with AraC, 5AC, DAC or Zeb. Cultures were performed in sequential triplicates. Rows represent DNA from individual cultures. Columns represent a single CpG site or a combination of CpG sites. Color coding reflects the degree of methylation (blue, 100%; light green, 0%; gray, no data). Average methylation for each amplicon is displayed as bar chart.

Back to article page